Isolated Testicular Relapse Five Years After Cessation of Chemotherapy for Acute Lymphoblastic Leukemia

Chu, Jhih‐Wei; O’Connor, Dennis M.; Cradock, Thomas V.; Gale, Gordon B.

doi:10.1177/000992288202100612

Cited by 3 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, this polarized distribution of ENT1 and ENT2 establishes a Na +independent transepithelial transport pathway to deliver xenobiotics across the BTB into the male genital tract for treating viral infections, cancers, and other testicular DMD-MR-2022-001186R1 indications. One such example of a nucleoside analog therapeutic used to treat leukemias, which can reside in the sanctuary site afforded by the BTB (Bowman et al, 1984;Chu et al, 1982;Gajjar et al, 1996;Grundy et al, 1997;Heaney et al, 1983;Kulkarni et al, 2010;Nesbit et al, 1980;Ritzen, 1990;Shaffer et al, 1992;Tombolini et al, 1986), is clofarabine. It is also known to cause toxicities in many organs, including in the seminiferous tubules of rodents and canines (U.S. Food and Drug Administration, 2004).…”

Section: Nucleoside Transportersmentioning

confidence: 99%

Drug Transporters at the Human Blood-Testis Barrier

2023

View full text Add to dashboard Cite

Transporters are involved in the movement of many physiologically important molecules across cell membranes and have a substantial impact on the pharmacological and toxicological effect of xenobiotics. Many transporters have been studied in the context of disposition to, or toxicity in, organs like the kidney and liver; however, transporters in the testes are increasingly gaining recognition for their role in drug transport across the blood-testis barrier (BTB). The BTB is an epithelial membrane barrier formed by adjacent Sertoli cells (SCs) in the seminiferous tubules that form intercellular junctional complexes to protect developing germ cells from the external environment. Consequently, many charged or large polar molecules cannot cross this barrier without assistance from a transporter. SCs express a variety of drug uptake and efflux transporters to control the flux of endogenous and exogenous molecules across the BTB. Recent studies have identified several transport pathways in SCs that allow certain drugs to circumvent the human BTB. These pathways may exist in other species, such as rodents and nonhuman primates; however, there is (1) a lack of information on their expression and/or localization in these species and (2) conflicting reports on localization of some transporters that have been evaluated in rodents compared to humans. This review outlines the current knowledge on the expression and localization of pharmacologically relevant drug transporters in human testes and calls attention to the insufficient and contradictory understanding of testicular transporters in other species that are commonly used in drug disposition and toxicity studies.

show abstract

Section: Nucleoside Transportersmentioning

confidence: 99%

Drug Transporters at the Human Blood-Testis Barrier

2023

View full text Add to dashboard Cite

show abstract

Relapse of precursor B-cell acute lymphoblastic leukemia as an isolated central nervous system mass lesion 9 years after initial diagnosis

Lowichik¹,

Bernini²,

Tonk³

et al. 1996

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

Extramedullary recurrence of acute lymphoblastic leukemia 15 years after initial diagnosis

Burton

Weinberg

Borowitz

1984

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

We describe a 19-year-old man with recurrence of a lymphoid malignancy involving the ethmoid sinus 15 years following diagnosis and 10 years after discontinuation of therapy for childhood acute lymphoblastic leukemia (ALL). The cytologic appearance and immunologic phenotype of the tumor cells suggest that this malignancy represents a recurrence of his original tumor. Initial relapse of ALL is unusual after 4 years of continuous remission off therapy. This case illustrates that late relapse can occur and may present with unusual sites of involvement.

show abstract

Isolated Testicular Relapse Five Years After Cessation of Chemotherapy for Acute Lymphoblastic Leukemia

Cited by 3 publications

References 10 publications

Drug Transporters at the Human Blood-Testis Barrier

Drug Transporters at the Human Blood-Testis Barrier

Relapse of precursor B-cell acute lymphoblastic leukemia as an isolated central nervous system mass lesion 9 years after initial diagnosis

Extramedullary recurrence of acute lymphoblastic leukemia 15 years after initial diagnosis

Contact Info

Product

Resources

About